HOUSTON -- A prominent cardiologist told a government official that Merck & Co. had engaged in "scientific misconduct" in its handling of its Vioxx painkiller, according to evidence presented in a federal trial here.
<snip>
Under questioning, Dr. Topol described how he concluded Vioxx increases heart-attack risks in a study he published in August 2001 in the Journal of the American Medical Association. Prior to publishing, Dr. Topol sent Merck a draft of his paper.
He testified Merck scientists visited him in Cleveland to tell him he "got it wrong" and would be "embarrassed" if his paper were to appear.Dr. Topol challenged Merck's explanation for the results of a 2000 study that compared Vioxx with naproxen, an older painkiller, in which patients on Vioxx had four to five times as many heart attacks. Merck had concluded naproxen worked to protect the heart, but Dr. Topol said "the only appropriate conclusion" was that Vioxx had a problem.
Following the withdrawal of Vioxx, Dr. Topol sent an email to David Graham, a Food and Drug Administration official, that said he was "bothered" by Merck's "scientific misconduct," which he felt didn't receive adequate attention.
http://online.wsj.com/article/SB113365948152113429.html?mod=us_